GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Intrinsic Value: Projected FCF

ANL (Adlai Nortye) Intrinsic Value: Projected FCF : $0.00 (As of May. 30, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-05-30), Adlai Nortye's Intrinsic Value: Projected FCF is $0.00. The stock price of Adlai Nortye is $1.995. Therefore, Adlai Nortye's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Adlai Nortye's Intrinsic Value: Projected FCF or its related term are showing as below:

ANL's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.17
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Adlai Nortye Intrinsic Value: Projected FCF Historical Data

The historical data trend for Adlai Nortye's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Intrinsic Value: Projected FCF Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
- - - -

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24 Dec24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Adlai Nortye's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Adlai Nortye's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adlai Nortye's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Price-to-Projected-FCF falls into.


;
;

Adlai Nortye Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Adlai Nortye  (NAS:ANL) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Adlai Nortye's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.995/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adlai Nortye Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Adlai Nortye Business Description

Industry
Traded in Other Exchanges
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.